The global liquid biopsy market size is expected to be worth around US$ 7.96 billion by 2030 from valued at US$ 33.49 Million in 2020 with a CAGR of 23.4% during forecast period 2021 to 2030.
The global liquid biopsy market size is expected to be worth around US$ 7.96 billion by 2030 from valued at US$ 33.49 Million in 2020 with a CAGR of 23.4% during forecast period 2021 to 2030.
The increasing prevalence of cancer coupled with the rise in demand for fast, minimally invasive diagnostic tests drives the market growth. It aids in the detection and isolation of circulating tumor DNA, exosomes, and circulating tumor cells and is a source of proteomics and genomics information in cancer patients. Rapid development in digital Polymerase Chain Reaction (PCR) and NGS-based technology has improved the accuracy of liquid biopsy. It can be performed repeatedly for disease monitoring and is anticipated to help overcome the limitations of tissue biopsies.
Get the sample copy of report@ https://www.visionresearchreports.com/report/sample/37723
As liquid biopsies are the most promising novel techniques for cancer care, established as well as emerging companies have increased their R&D to develop novel liquid biopsy solutions. For instance, in September 2021, AnchorDx Medical Co., Ltd.; a China-based developer of early cancer detection and oncology screening solutions developed a diagnostic model for early breast cancer detection. The model is based on the methylation patterns of cfDNA.
Report Coverage
| Report Scope | Details |
| Market Size | USD 7.96 billion by 2030 |
| Growth Rate | CAGR of 23.4% From 2021 to 2030 |
| Base Year | 2021 |
| Forecast Period | 2021 to 2030 |
| Segments Covered | Application, Sample Type, Biomarker, Technology |
| Regional Scope | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
| Companies Mentioned | Guardant Health, Personal Genome Diagnostics, Biocept, Adaptive Biotechnologies, Cynvenio, NeoGenomics Laboratories, Qiagen, Trovagene, and RainDance Technologies. |
Technology Insights
The Multi-gene-parallel Analysis (NGS) segment accounted for the largest revenue share of over 73% of the global market in 2020 and is anticipated to maintain its dominance over the forecast period. NGS technology can detect various mutations that could be responsible for tumorigenesis and detect resistance mechanisms that may have developed from pre-existing clones after treatment.
Recently, rapid developments in NGS technology have led to significant cost reduction in sequencing with high accuracy. This technology is used in targeted panels for specific and highly sensitive ctDNA mutation detection and allows screening of unknown variants. For instance, NGS can detect 59% of stage 1 or 2 lung cancer patients with MAF around 0.1%.
Furthermore, key operating players have introduced innovative products, thus driving the market. For instance, in February 2021, Twist Bioscience Corp. launched Twist NGS Methylation Detection System for liquid biopsy cancer analysis and epigenetic studies. In addition, in April 2021, Biodesix, Inc. declared its plan to launch a blood-based 52-gene NGS test to enhance its portfolio of molecular testing.
Biomarker Insights
Circulating Nucleic Acids accounted for the largest revenue share of 36.68% in 2020. Wide applications of circulating tumor DNA (ctDNA) in liquid biopsy of cancer drives the segment. Over the recent years, ctDNA-based liquid biopsy analysis has created new opportunities in molecular diagnosis and monitoring of cancer. It is capable of precisely determining tumor progression, prognosis, and assisting in targeted therapy.
Translational cancer researchers are using liquid biopsies to identify ctDNA from tumors. The detection of ctDNA serves as a potential biomarker and provides a great opportunity in future liquid biopsy applications for cancer detection. Compared to invasive procedures, ctDNA has been provided as an alternative source to carry out molecular profiling of tumor DNA in patients with cancer.
Exosomes/Microvesicles are anticipated to grow with the fastest CAGR from 2021 to 2028. A rise in the adoption of exosomes as a liquid biopsy in oncology clinical diagnosis coupled with the introduction of novel products drives the segment growth. In September 2021, miR Scientific presented data for its miR Sentinel Prostate Cancer Test at the American Urological Association’s (AUA) 2021 Annual Meeting. This exosome-based liquid biopsy test uses a single urine sample to detect prostate cancer with an accuracy of 90%.
Ask here for more details@ https://www.visionresearchreports.com/report/enquiry/37723
Sample Type Insights
Blood sample-based tests dominated the market with a revenue share of over 69%. A blood-based test is non-invasive, has no risk, and is painless. In addition, it reduces the cost and time taken for diagnosis. CTCs, cfDNAs, and exosomes, as well as microvesicles, can be detected in the blood sample, thus increasing the adoption of blood-based liquid biopsy.
The circulating biomarkers in blood play a vital role in understanding tumorigenesis and metastasis, which further can help determine tumor dynamics at the time of treatment and disease progression. In addition, ongoing research on blood-based tests for cancer is expected to drive the market.
For instance, in August 2021, a research group at Exact Sciences and UW-Madison started working on liquid biopsies for cancer, including a blood test that helps detect genetic mutations in tumors targeted by drugs. This test can detect recurrence of cancer after treatment as well as help in the early detection of the disease.
Regional Insights
North America accounted for the largest revenue share of over 51% in 2020. The regional market is led by the U.S. owing to greater investments and the presence of a number of biotechnology companies developing the tests. Various organizations, such as the American Society of Clinical Oncology (ASCO), aid the implementation of liquid biopsy. This, in turn, is anticipated to boost the market growth in this region.
Canada follows the U.S. in the adoption of liquid biopsy tests, as FDA-approved tests are permitted to be used in the country. Moreover, many biotechnology companies are competing in the market, which is expected to drive market growth during the forecast period. An increase in grants and investments by the government for the development of liquid biopsy tests is expected to boost the market in the country.
For instance, in June 2021, BioMark Diagnostic Solutions, Inc. received USD 825,000 funding to develop BioMark’s liquid biopsy assay for screening lung cancer. A major part of the funding is being issued by Consortium for Industrial Research and Innovation in Medical Technology and Spark grants from the Canadian Cancer Society, Brain Canada Foundation, and Canadian Institutes of Health Research - Institute of Cancer Research.
Key Players
The key players operating in the market are Guardant Health, Personal Genome Diagnostics, Biocept, Adaptive Biotechnologies, Cynvenio, NeoGenomics Laboratories, Qiagen, Trovagene, and RainDance Technologies.
Market Segmentation
- Application Outlook
- Therapy Selection for Metastatic Breast Cancer (MBS)
- Therapy Selection for Other Metastatic Cancer
- Molecular Health Monitoring
- Sample Type Outlook
- Blood Sample based
- Urine Sample based
- Other Bio Fluids (Tissue fluids and Saliva) based
- Biomarker Outlook
- Circulating Tumor Cells (CTC)
- Circulating Tumor DNA (ctDNA)
- Exosomes
- Technology Outlook
- Multi-gene-parallel Analysis (NGS)
- Single Gene Analysis (PCR Microarrays)
- Regional Outlook
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Click Here to View Full Report Table of Contents
Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/37723
You can place an order or ask any questions, please feel free to contact at sales@visionresearchreports.com | +1 9197 992 333